Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 92Triple Negative Breast Neoplasms 39Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 10Neoplasms 8Stomach Neoplasms 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Colorectal Neoplasms 6Melanoma 5Cholangiocarcinoma 5Sarcoma 4Prostatic Neoplasms 4Lung Neoplasms 4Inflammatory Breast Neoplasms 4Breast Neoplasms, Male 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Gallbladder Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Colonic Neoplasms 3Carcinoma, Hepatocellular 3Carcinoma, Ductal, Breast 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Mesothelioma, Malignant 2Mesothelioma 2Lymphoma, Non-Hodgkin 2

Interventions

eribulin 3Vinorelbine 2Paclitaxel 2Epirubicin 2Doxorubicin 2Cyclophosphamide 2trastuzumab deruxtecan 1tislelizumab 1taxane 1sacituzumab govitecan 1pembrolizumab 1pamiparib 1liposomal doxorubicin 1camrelizumab 1anlotinib 1Taxes 1Precision Medicine 1Gemcitabine 1Docetaxel 1Cisplatin 1Carboplatin 1Capecitabine 1Anthracyclines 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-negative Breast Cancer × Cisplatin × Breast × Clear all
NCT04848454 2022-10-18

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

Peking University First Hospital

Phase 2 Unknown
30 enrolled
Breast

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡